Stock listing

NASDAQ:CRBU Caribou Biosciences, Inc. Stock

Home listing (NASDAQ) of Caribou Biosciences, Inc.

Follow Caribou Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CRBU

$0.284 USD -0.042 (-12.8%)

Close on Nov 20, 2026

Past year -83.8% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.282 – $0.305 USDNov 20, 2026
Volume
3.26M sharesNov 20, 2026
Market cap
$30.71M USDAt the close on Nov 20, 2026 · price × 108.0M shares outstanding
52-week range
$0.282 – $2.490 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$1.96M USDMedian day 1.69M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Caribou Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CRBU · Home$0.284 USD-0.042 (-12.8%)3,256,041$0.300$0.305$0.282$0.326Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRBU · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.284-0.042-12.8%$0.300$0.305$0.2823,256,041
$0.326-0.015-4.3%$0.340$0.349$0.3113,372,296
$0.341-0.012-3.4%$0.345$0.353$0.3252,566,359
$0.353-0.009-2.5%$0.360$0.365$0.3502,149,099
$0.362-0.018-4.8%$0.384$0.384$0.3601,737,983
$0.380-0.011-2.7%$0.388$0.388$0.3651,539,115
$0.391-0.020-4.8%$0.400$0.404$0.3652,939,655
$0.410-0.009-2.2%$0.410$0.430$0.3901,639,705
$0.420-0.029-6.4%$0.440$0.460$0.4093,258,357
$0.449+0.036+8.8%$0.401$0.449$0.4011,702,305
$0.412-0.032-7.2%$0.438$0.441$0.4031,904,662
$0.444-0.015-3.3%$0.459$0.473$0.4371,232,951
$0.459+0.019+4.4%$0.427$0.465$0.4151,379,687
$0.440+0.017+3.9%$0.435$0.450$0.4103,304,685
$0.423-0.022-4.9%$0.445$0.445$0.4142,306,242
$0.445-0.044-9.1%$0.487$0.500$0.4452,837,479
$0.489+0.029+6.2%$0.469$0.492$0.4611,024,941
$0.461-0.032-6.4%$0.487$0.495$0.4552,368,163
$0.492-0.041-7.6%$0.533$0.536$0.4911,934,025
$0.533-0.027-4.9%$0.550$0.577$0.5332,155,513
$0.560+0.016+2.9%$0.528$0.564$0.5212,784,450
$0.544+0.025+4.9%$0.520$0.550$0.5122,264,019
$0.519+0.055+11.9%$0.469$0.525$0.4633,411,959
$0.464-0.006-1.3%$0.464$0.478$0.4593,801,304
$0.470+0.005+1.1%$0.470$0.478$0.4492,945,171
$0.465+0.005+1.0%$0.460$0.477$0.4472,881,415
$0.460-0.010-2.1%$0.477$0.484$0.4453,709,542
$0.470-0.027-5.4%$0.482$0.495$0.4504,546,001
$0.497+0.037+8.0%$0.452$0.507$0.4455,264,111
$0.460-0.021-4.4%$0.460$0.519$0.4439,738,162
$0.481-0.136-22.1%$0.594$0.597$0.45019,344,000
$0.617-0.518-45.6%$0.636$0.670$0.54637,509,910
$1.135-0.055-4.6%$1.190$1.215$1.1305,939,336
$1.190-0.030-2.5%$1.220$1.240$1.1701,546,867
$1.2200.0000.0%$1.240$1.240$1.215866,573
$1.220-0.050-3.9%$1.270$1.285$1.220687,396
$1.270+0.030+2.4%$1.278$1.285$1.250845,066
$1.240+0.010+0.8%$1.250$1.265$1.220637,084
$1.230-0.010-0.8%$1.250$1.260$1.220818,632
$1.240-0.010-0.8%$1.250$1.270$1.220901,267
$1.250-0.040-3.1%$1.290$1.290$1.250978,905
$1.290-0.050-3.7%$1.340$1.360$1.290700,029
$1.340+0.040+3.1%$1.320$1.360$1.3101,217,330
$1.3000.0000.0%$1.310$1.350$1.290753,310
$1.300-0.010-0.8%$1.330$1.340$1.3001,853,974
$1.310+0.060+4.8%$1.270$1.330$1.2601,257,062
$1.250-0.020-1.6%$1.280$1.290$1.250969,353
$1.270-0.020-1.6%$1.310$1.310$1.2501,692,439
$1.290+0.020+1.6%$1.275$1.330$1.2501,685,847
$1.270-0.100-7.3%$1.380$1.400$1.2602,433,878
$1.370-0.070-4.9%$1.430$1.440$1.3501,261,006
$1.440-0.100-6.5%$1.540$1.540$1.4401,768,265
$1.540-0.030-1.9%$1.570$1.580$1.540717,627
$1.5700.0000.0%$1.570$1.600$1.5501,329,447
$1.570-0.030-1.9%$1.610$1.610$1.5331,349,959
$1.600+0.050+3.2%$1.550$1.625$1.550770,671
$1.550+0.010+0.6%$1.530$1.590$1.519756,279
$1.540-0.080-4.9%$1.610$1.630$1.5251,010,331
$1.620-0.040-2.4%$1.660$1.670$1.600666,589
$1.660+0.010+0.6%$1.670$1.690$1.640901,154
$1.650-0.110-6.3%$1.750$1.750$1.640841,305
$1.760+0.120+7.3%$1.650$1.760$1.6501,380,392
$1.640-0.020-1.2%$1.680$1.690$1.610762,660
$1.660+0.050+3.1%$1.640$1.690$1.6151,162,457
$1.610-0.030-1.8%$1.640$1.650$1.580892,576
Ticker
NASDAQ:CRBU
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Caribou Biosciences, Inc. news

Caribou Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
17 in the last 12 months · 99 in all · newest Nov 5, 2026 · oldest 2021
Decks
13 decks · latest Feb 7, 2026

Where Caribou Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CRBU · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CRBUBOATSUnited StatesUSD

Valuation

EV/sales −4.0× against a median of 25.3×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$37.75M USD
P/E
Loss
EV/sales
−4.0×
EV/EBITDA
Negative EBITDA
Price/book
0.4×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.3×
Beta vs S&P 500
1.87

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Caribou Biosciences, Inc. · NASDAQ:CRBUUS$30.71M−US$37.75Mn/a−4.0×n/a0.4×n/a0.3×1.87
Enimmune Corporation · TPEX:6564US$31.74MUS$26.88Mn/a18.4×n/a10.4×−341.0%0.3×n/a
Molecure SA · GPW:MOCUS$31.65MUS$29.59Mn/an/an/a1.3×n/a0.0×n/a
Sareum Holdings plc · LSE:SARUS$31.06MUS$27.80Mn/an/an/a19.9×n/a0.0×n/a
Isofol Medical AB · OMXSTO:ISOFOLUS$31.05MUS$19.81Mn/an/an/a3.3×n/a0.0×n/a
Filana Therapeutics, Inc. · NASDAQ:FLNAUS$30.98M−US$16.01Mn/an/an/a0.5×n/a0.0×1.25
Avecho Biotechnology Limited · ASX:AVEUS$30.77MUS$26.53Mn/a32.3×n/a24.3×−356.8%0.1×n/a
Kalaris Therapeutics, Inc. · NASDAQ:KLRSUS$30.47M−US$51.05Mn/an/an/a0.6×n/a0.0×0.47
Pacific Software, Inc. · OTC:PFSFUS$29.86MUS$38.10Mn/an/an/an/an/an/a1.57
NextCure, Inc. · NASDAQ:NXTCUS$29.53MUS$20.81Mn/an/an/a5.4×n/a0.0×1.85
NurExone Biologic Inc · TSXV:NRXUS$29.53MUS$28.52Mn/an/an/a23.3×n/a0.0×0.00
Median of the othersUS$30.88MUS$26.71M25.3×5.4×−348.9%0.0×1.25

Forecasts

1 strong buy · 4 hold · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
5.00 USD · Analysts' mean
EPS, year to Dec 2026
-1.03 · 4 analysts
Revenue, year to Dec 2026
25.72M · 5 analysts

Team and board

Officers

OfficerRole
Dara Richardson-HeronChief Executive Officer
Nancy WhitingPresident and Chief Executive Officer
Rachel HaurwitzPresident and chief executive officer
Ran ZhengChief Executive Officer
Andrew GuggenhimePresident and Chief Financial Officer
Sri RyaliChief Financial Officer
David JohnsonChief Operating Officer
Barbara McClungChief Legal Officer and Corporate Secretary
Enrique ZudaireSenior Vice President, Translational Research
Justin SkobleSenior Vice President, Technical Operations
Reigin ZawadzkiChief People Officer
Tina AlbertsonChief Medical Officer

Board

DirectorRole
Andrew GuggenhimePresident and Chief Financial Officer
Dara Richardson-HeronChief Executive Officer
David JohnsonChief Operating Officer
Nancy WhitingPresident and Chief Executive Officer
Natalie SacksPartner at Novo Holdings Ventures Investment
Rachel HaurwitzPresident and chief executive officer
Ran ZhengChief Executive Officer
Scott BraunsteinOperating Partner

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+8.8%
Q2 2026Aug 13, 2026 · After close−1.9%
Q1 2026May 7, 2026 · After close+3.2%
Q4 2025Mar 16, 2026+4.8%
Q3 2025Nov 12, 2025 · After close−12.2%
Q2 2025Aug 12, 2025 · After close+8.9%
Q1 2025May 8, 2025 · After close−2.0%
Q4 2024Mar 10, 2025−7.8%
Q3 2024Nov 6, 2024 · After close+1.1%
Q2 2024Aug 6, 2024 · After close−2.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · After close−6.2%
Q4 2023Mar 11, 2024 · After close−30.5%
Q3 2023Nov 7, 2023 · After close−5.0%
Q2 2023Aug 8, 2023 · After close+5.8%
Q1 2023May 9, 2023 · After close+6.8%
Q4 2022Mar 9, 2023 · After close−6.0%
Q3 2022Nov 8, 2022 · After close+0.8%
Q2 2022Aug 9, 2022 · After close+14.3%
Q1 2022May 9, 2022 · After close+9.3%
Q4 2021Mar 21, 2022 · After close+9.5%

Open Events

Decks

DeckKindSlidesDate
2026 Tandem MeetingsConference19 slidesFeb 7, 2026
Technical Presentation (2026)Technical16 slides2026
EHA 2026Conference16 slides2026
Technical Presentation (June 2024)Technical47 slidesJun 3, 2024
Technical Presentation (June 2024)Technical47 slidesJun 2, 2024
Investor Presentation (May 2024)Investor deck46 slidesMay 7, 2024
Technical Presentation (April 2024)Technical12 slidesApr 20, 2024
Corporate Update (April 2024)Corporate update19 slidesApr 4, 2024
Corporate Update (July 2023)Corporate update36 slidesJul 13, 2023
Technical Presentation (July 2023)Technical37 slidesJul 13, 2023
All 13 decks
DeckKindSlidesDate
Technical Presentation (July 2023)Technical11 slidesJul 13, 2023
Technical Presentation (June 2022)Technical31 slidesJun 10, 2022
Corporate Update (May 2022)Corporate update19 slidesMay 12, 2022

Open Decks

IPO

Priced at US$16.00 a share on Jul 22, 2021.

Price
US$16.00 a share
Shares offered
19,000,000 shares of common stock
Offering size
US$304 million
Underwriters' option
Up to 2,850,000 more shares
Underwriters
BofA Securities, Citigroup, SVB Leerink · In the order on the cover
Shares delivered
On or about Jul 27, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceMay 7, 2021
Filed publiclyJul 1, 2021
Amended twiceNewest Jul 22, 2021
Shares registered with an exchangeJul 19, 2021
Declared effective by the SECJul 22, 2021
Final prospectus, with the priceJul 23, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Jul 23, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue11.2M9.99M34.5M13.9M9.60M12.4M5.79M
Cost of revenue3.65M3.93M3.52M3.64M984.0K34.4M23.6M
Gross profit7.51M6.07M31.0M10.2M8.61M-22.1M5.79M
Research and development109.4M130.2M112.1M82.2M52.3M34.4M23.6M
Selling, general and administrative37.9M46.5M38.5M38.0M24.3M14.1M16.5M
Operating income-148.3M-166.6M-116.1M-106.4M-67.0M-36.1M-34.3M
Depreciation and amortization3.65M3.93M3.52M1.62M984.0K900.0K751.0K
EBITDA-144.7M-162.7M-112.5M-104.8M-66.0M-35.2M-33.6M
Interest expense8.54M8.00K20.0K4.00K
Income before tax-148.7M-149.1M-101.9M-99.4M-66.6M-36.1M-31.0M
Income tax-550.0K-9.00K193.0K70.0K321.0K-1.82M-7.54M
Net income-148.1M-149.1M-102.1M-99.4M-66.9M-34.3M-23.4M
Earnings per share, basic-1.59-1.65-1.38-1.64-2.11-4.01-2.80
Earnings per share, diluted-1.59-1.65-1.38-1.64-2.11-4.01-2.80

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash and equivalents12.4M16.3M51.2M58.3M240.4M16.0M41.1M
Short-term investments127.0M193.2M277.7M189.3M135.4M08.40M
Receivables69.0K265.0K148.0K202.0K1.15M150.0K3.98M
Inventory-62.6M-31.1M2.43M3.18M
Current assets145.2M219.4M338.8M260.2M391.2M24.3M57.0M
Property, plant and equipment6.76M19.3M18.3M10.7M4.89M3.50M4.33M
Total assets175.4M313.3M432.2M373.8M442.4M36.0M61.9M
Accounts payable5.78M2.48M3.12M1.15M3.99M2.60M2.54M
Current liabilities25.4M30.7M28.3M28.1M25.8M12.4M10.1M
Long-term debt924.0K
Total debt27.2M26.5M27.1M27.7M259.0K1.58M532.0K
Total liabilities53.2M60.4M63.8M72.9M54.5M18.2M54.5M
Shareholders' equity122.2M253.0M368.4M300.9M387.8M-23.4M7.46M
Shares outstanding95.1M92.4M88.4M61.0M60.3M9.71M60.7M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations-111.0M-138.2M-93.3M-91.0M-32.5M-33.2M-32.0M
Capital spending-1.36M-4.88M-11.6M-6.45M-2.12M-317.0K-884.0K
Free cash flow-112.4M-143.1M-104.9M-97.4M-34.6M-33.5M-32.9M
Cash from investing102.2M86.6M-68.2M-93.2M-176.4M6.36M27.2M
Cash from financing4.82M16.7M154.3M2.13M433.4M1.74M172.0K
Share buybacks432.4M
Change in cash-3.93M-34.9M-7.18M-182.1M224.5M-25.1M-4.60M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
8-K · Current reportOct 6, 2026Management or board changeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
8-K · Current reportJun 18, 2026Meeting outcomeSEC
8-K · Current reportJun 11, 2026Current reportSEC
DEFA14A · Additional proxy materialJun 5, 2026Meeting noticeSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportMay 7, 2026ResultsSEC
DEFR14AMay 1, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 24, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 24, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 24, 2026Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 10, 2026Meeting noticeSEC
8-K · Current reportMar 31, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 5, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
144 · Notice of proposed saleFeb 25, 2026Other filingsSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportNov 3, 2025ResultsSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 12, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
8-K · Current reportJun 23, 2025Current reportSEC
8-K · Current reportJun 13, 2025Meeting outcomeSEC
EFFECT · Notice that a registration is effectiveMay 15, 2025Other filingsSEC
CORRESP · Letter to the SECMay 13, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 12, 2025Other filingsSEC
DEFA14A · Additional proxy materialMay 8, 2025Meeting noticeSEC
S-3 · Registration statementMay 8, 2025Offer documentSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
8-K · Current reportMay 8, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 30, 2025Big-stake noticeSEC
SCHEDULE 13D · Big-stake noticeApr 25, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
8-K · Current reportApr 24, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 11, 2025Meeting noticeSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 10, 2025Offer documentSEC
10-K · Annual reportMar 10, 2025Annual reportSEC
8-K · Current reportMar 10, 2025ResultsSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
8-K · Current reportJan 13, 2025Current reportSEC
4 · Change in ownershipJan 10, 2025Insider tradeSEC
3 · Initial statement of ownershipJan 10, 2025Insider tradeSEC
8-K · Current reportJan 2, 2025Management or board changeSEC
SC 13D/A · Big-stake notice, amendedDec 6, 2024Big-stake noticeSEC
4 · Change in ownershipNov 22, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 6, 2024Quarterly reportSEC
8-K · Current reportNov 6, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 4, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedOct 17, 2024Big-stake noticeSEC
3 · Initial statement of ownershipOct 4, 2024Insider tradeSEC
8-K/A · Current report, amendedSep 27, 2024Management or board changeSEC
8-K · Current reportSep 3, 2024Management or board changeSEC
4 · Change in ownershipAug 20, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 20, 2024Insider tradeSEC
8-K · Current reportAug 12, 2024Current reportSEC
10-Q · Quarterly reportAug 6, 2024Quarterly reportSEC
8-K · Current reportAug 6, 2024ResultsSEC
8-K · Current reportJul 16, 2024ResultsSEC
8-K · Current reportJun 14, 2024Meeting outcomeSEC
8-K · Current reportJun 3, 2024Current reportSEC
10-Q · Quarterly reportMay 7, 2024Quarterly reportSEC
8-K · Current reportMay 7, 2024ResultsSEC
ARS · Annual report to shareholdersApr 25, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2024Meeting noticeSEC
8-K · Current reportApr 4, 2024Current reportSEC
S-8 · Registration statement for employee plansMar 11, 2024Offer documentSEC
10-K · Annual reportMar 11, 2024Annual reportSEC
8-K · Current reportMar 11, 2024ResultsSEC
SC 13G · Big-stake noticeFeb 23, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
4 · Change in ownershipFeb 22, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
4 · Change in ownershipFeb 8, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 25, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedJan 25, 2024Big-stake noticeSEC
3/A · Initial statement of ownership, amendedJan 10, 2024Insider tradeSEC
4 · Change in ownershipJan 9, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 9, 2024Insider tradeSEC
SC 13G · Big-stake noticeJan 8, 2024Big-stake noticeSEC
8-K · Current reportJan 8, 2024Current reportSEC
8-K · Current reportDec 22, 2023Management or board changeSEC
8-K · Current reportDec 12, 2023Management or board changeSEC
10-Q/A · Quarterly report, amendedNov 17, 2023Quarterly reportSEC
10-Q/A · Quarterly report, amendedNov 17, 2023Quarterly reportSEC
10-Q · Quarterly reportNov 7, 2023Quarterly reportSEC
8-K · Current reportNov 7, 2023ResultsSEC
8-K · Current reportOct 18, 2023Current reportSEC
8-K · Current reportSep 26, 2023Current reportSEC
10-Q · Quarterly reportAug 8, 2023Quarterly reportSEC
8-K · Current reportAug 8, 2023ResultsSEC
SC 13G · Big-stake noticeJul 20, 2023Big-stake noticeSEC
8-K · Current reportJul 14, 2023Material contractSEC
424B5 · ProspectusJul 14, 2023Offer documentSEC
8-K/A · Current report, amendedJul 14, 2023Current reportSEC
424B5 · ProspectusJul 13, 2023Offer documentSEC
8-K · Current reportJul 13, 2023ResultsSEC
8-K · Current reportJul 13, 2023Current reportSEC
SC 13G · Big-stake noticeJul 10, 2023Big-stake noticeSEC
8-K · Current reportJul 6, 2023Material contractSEC
8-K · Current reportJun 16, 2023Meeting outcomeSEC
4 · Change in ownershipJun 9, 2023Insider tradeSEC
10-Q · Quarterly reportMay 9, 2023Quarterly reportSEC
8-K · Current reportMay 9, 2023ResultsSEC
ARS · Annual report to shareholdersApr 28, 2023Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2023Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2023Meeting noticeSEC
8-K · Current reportApr 4, 2023Current reportSEC
8-K · Current reportMar 29, 2023Current reportSEC
8-K · Current reportMar 29, 2023Current reportSEC
8-K · Current reportMar 24, 2023Current reportSEC
4 · Change in ownershipMar 22, 2023Insider tradeSEC
S-8 · Registration statement for employee plansMar 9, 2023Offer documentSEC
10-K · Annual reportMar 9, 2023Annual reportSEC
8-K · Current reportMar 9, 2023ResultsSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
4 · Change in ownershipFeb 23, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2023Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 3, 2023Big-stake noticeSEC
SC 13G · Big-stake noticeFeb 3, 2023Big-stake noticeSEC
4 · Change in ownershipJan 20, 2023Insider tradeSEC
8-K · Current reportDec 16, 2022Management or board changeSEC
8-K · Current reportDec 12, 2022Current reportSEC
4 · Change in ownershipDec 2, 2022Insider tradeSEC
8-K · Current reportNov 29, 2022Current reportSEC
8-K · Current reportNov 21, 2022Current reportSEC
10-Q · Quarterly reportNov 8, 2022Quarterly reportSEC
8-K · Current reportNov 8, 2022ResultsSEC
8-K · Current reportNov 3, 2022Current reportSEC
8-K · Current reportOct 18, 2022Current reportSEC
4 · Change in ownershipOct 7, 2022Insider tradeSEC
8-K/A · Current report, amendedSep 22, 2022Meeting outcomeSEC

This page holds 200 of 326 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Caribou Biosciences, Inc.’s releases · as of Nov 2, 2026

Common shares
108,036,729
Fully diluted
108,036,729

Fully diluted

LineSharesAs of
Common shares108,036,729Nov 2, 2026

Share count over time

CountShares
Nov 2, 2026108,036,729

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueChange vs Jun 30Filed
BlackRock8.14M7.5%US$10.3M+327KNov 13, 2026
Vanguard5.84M5.4%US$7.42M+347KNov 16, 2026
Pfizer Inc4.69M4.3%US$5.82MNo changeNov 12, 2026
Mackenzie4.07M3.8%US$5.17M+421KNov 2, 2026
Renaissance Technologies2.56M2.4%US$3.25M−218KNov 12, 2026
Kynam Capital Management, LP2.5M2.3%US$3.18MNo changeNov 16, 2026
Geode Capital2.44M2.3%US$3.1M+63,884Nov 6, 2026
Bank of America1.74M1.6%US$2.21M+327KNov 16, 2026
AQR Capital Management LLC1.63M1.5%US$2.07MNewNov 16, 2026
State Street1.53M1.4%US$1.94M−106KNov 12, 2026
Show 50 holders
HolderSharesOf the companyValueChange vs Jun 30Filed
Acadian Asset Management LLC1.45M1.3%US$1.85M−320KNov 9, 2026
Qube Research & Technologies Ltd1.12M1.0%US$1.42M+574KNov 13, 2026
Fidelity1.08M1.00%US$1.37M+348KNov 10, 2026
Schwab876K0.81%US$1.11M+100KNov 16, 2026
UBS824K0.76%US$1.05M+307KNov 10, 2026
Goldman Sachs805K0.75%US$1.02M+482KNov 16, 2026
Dimensional749K0.69%US$951K−227KNov 4, 2026
Northern Trust729K0.68%US$926K+16,332Nov 16, 2026
Two Sigma675K0.62%US$857K−372KNov 16, 2026
Morgan Stanley666K0.62%US$846K+544KNov 13, 2026
Maverick Capital LTD653K0.60%US$829KNo changeNov 16, 2026
Marshall Wace, LLP575K0.53%US$731K+200KNov 13, 2026
Gsa Capital Partners LLP552K0.51%US$700K+88,116Nov 16, 2026
Green Alpha Advisors, LLC551K0.51%US$700K+187KOct 8, 2026
72 Investment Holdings, LLC474K0.44%US$602KNo changeNov 16, 2026
Cambridge Investment Research Advisors, Inc.372K0.34%US$472K−393KNov 2, 2026
PFM Health Sciences, LP355K0.33%US$450KNo changeNov 16, 2026
Invesco348K0.32%US$441K+46,419Nov 12, 2026
Man Group plc328K0.30%US$416K+87,436Nov 16, 2026
XTX Topco Ltd289K0.27%US$367K+19,517Nov 16, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.257K0.24%US$326K+83,605Nov 16, 2026
Bruce & Co., Inc.250K0.23%US$318KNo changeNov 16, 2026
Wells Fargo237K0.22%US$301K−61,554Nov 16, 2026
BNY223K0.21%US$283KNo changeNov 5, 2026
Susquehanna207K0.19%US$263K−117KNov 16, 2026
Nuveen204K0.19%US$259K+80,591Nov 10, 2026
Milestone Asset Management, LLC203K0.19%US$257K+2,618Oct 15, 2026
Prudential Financial Inc199K0.18%US$253K+165KNov 16, 2026
Quadrature Capital Ltd147K0.14%US$187K+58,456Nov 13, 2026
American Century141K0.13%US$179KNo changeNov 20, 2026
Barclays130K0.12%US$165K+79,650Nov 6, 2026
BNP Paribas125K0.12%US$158K+53,607Nov 12, 2026
Bridgeway Capital Management, LLC122K0.11%US$155K−10,000Nov 16, 2026
Jacobs Levy Equity Management, Inc121K0.11%US$154K−290KNov 16, 2026
Nano Cap New Millennium Growth Fund L P118K0.11%US$149KNo changeNov 13, 2026
Employees Retirement System of Texas116K0.11%US$148KNewNov 10, 2026
Citadel107K0.10%US$136K+66,952Nov 16, 2026
Empowered Funds, LLC104K0.10%US$131KNewNov 13, 2026
Prime Capital Investment Advisors, LLC95,9450.09%US$122K+63,630Oct 20, 2026
T. Rowe Price91,7060.08%US$117KNewNov 16, 2026

This page holds 50 of 142 holders. Open Shareholders

Funds

HolderSharesOf the companyValueChangeAs of
Vanguard Total Stock Market Index Fund3.01M2.8%US$5.3M+285KJun 30, 2026
iShares Russell 2000 ETF2.29M2.1%US$4.03MNewJun 30, 2026
Vanguard Extended Market Index Fund1.11M1.0%US$1.96M+188KJun 30, 2026
Fidelity Small Cap Index Fund997K0.92%US$1.46MNewJul 31, 2026
iShares Russell 2000 Value ETF881K0.82%US$1.55MNewJun 30, 2026
iShares Biotechnology ETF629K0.58%US$1.11M+34,114Jun 30, 2026
Fidelity Extended Market Index Fund451K0.42%US$1.06M+27,626May 31, 2026
Schwab U.S. Small-Cap ETF425K0.39%US$1M−6,758May 31, 2026
iShares Micro-Cap ETF308K0.29%US$543KNewJun 30, 2026
Dimensional U.S. Small Cap ETF255K0.24%US$373K+38,046Jul 31, 2026
Show 50 holders
HolderSharesOf the companyValueChangeAs of
Bruce Fund250K0.23%US$440KNo changeJun 30, 2026
Schwab Small-Cap Index Fund224K0.21%US$326KNewJul 31, 2026
AXS Green Alpha ETF202K0.19%US$355K−9,520Jun 30, 2026
Master Small Cap Index Series172K0.16%US$302KNewJun 30, 2026
U.S. Small Cap Portfolio171K0.16%US$249KNo changeJul 31, 2026
Fidelity Total Market Index Fund149K0.14%US$351KNo changeMay 31, 2026
Avantis U.S. Small Cap Equity ETF134K0.12%US$315K+21,100May 31, 2026
Fidelity Small Cap Value Index Fund128K0.12%US$225KNewJun 30, 2026
Fidelity Series Total Market Index Fund127K0.12%US$300K+4,822May 31, 2026
Nuveen Small Cap Blend Index Fund124K0.11%US$180KNewJul 31, 2026
Ultra-Small Company Market Fund114K0.11%US$200KNo changeJun 30, 2026
U.S. Micro Cap Portfolio110K0.10%US$160K+55,840Jul 31, 2026
EQ/2000 Managed Volatility Portfolio99,8610.09%US$176KNewJun 30, 2026
Invesco RAFI US 1500 Small-Mid ETF82,3090.08%US$120K+41,642Jul 31, 2026
Schwab U.S. Broad Market ETF78,9960.07%US$186K+958May 31, 2026
Dimensional U.S. Core Equity 2 ETF74,9310.07%US$109K−20,956Jul 31, 2026
Fidelity Nasdaq Composite Index Fund72,6860.07%US$172KNo changeMay 31, 2026
Goldman Sachs Absolute Return Tracker Fund72,2620.07%US$127K+35,772Jun 30, 2026
LVIP State Street Small-Cap Index Fund70,2000.06%US$124KNewJun 30, 2026
Global X Genomics & Biotechnology ETF68,1840.06%US$161K+8,271May 31, 2026
Diversified Equity Alpha Master Portfolio67,3630.06%US$119K+53,306Jun 30, 2026
NVIT Multi-Manager Small Company Fund51,8740.05%US$91,298No changeJun 30, 2026
Vanguard Balanced Index Fund50,5670.05%US$88,998No changeJun 30, 2026
Small Cap Index Fund48,1450.04%US$84,735NewJun 30, 2026
Schwab Total Stock Market Index Fund46,9220.04%US$68,506No changeJul 31, 2026
Global X Russell 2000 ETF43,8830.04%US$64,069NewJul 31, 2026
Fidelity ZERO Total Market Index Fund43,7190.04%US$63,830No changeJul 31, 2026
Invesco NASDAQ Future Gen 200 ETF40,4380.04%US$95,434+6,359May 31, 2026
Small Cap Equity Fund40,3080.04%US$70,942−26,286Jun 30, 2026
NVIT Small Cap Value Fund39,6260.04%US$69,742No changeJun 30, 2026
Vanguard Institutional Total Stock Market Index Fund30,8130.03%US$54,231−31,348Jun 30, 2026
Fidelity ZERO Extended Market Index Fund30,0440.03%US$43,864+642Jul 31, 2026
Multi-Manager Small Cap Equity Strategies Fund29,4300.03%US$69,455−36,554May 31, 2026
State Street Small/Mid Cap Equity Index Portfolio29,0000.03%US$51,040NewJun 30, 2026
Small-Cap Index Portfolio26,4460.02%US$46,545NewJun 30, 2026
iShares Russell Small/Mid-Cap Index Fund24,1280.02%US$35,227NewJul 31, 2026
Small Cap Index Trust21,3670.02%US$37,606NewJun 30, 2026
1290 VT Micro Cap Portfolio20,7600.02%US$36,538NewJun 30, 2026
NVIT Small Cap Index Fund20,7090.02%US$36,448NewJun 30, 2026
ATM Small Cap Managed Volatility Portfolio20,5620.02%US$36,189NewJun 30, 2026

This page holds 50 of 88 holders. Open Shareholders

Big stakes

HolderStakeSharesDate
BlackRock, Inc.7.20%7.18MJun 30, 2026
Rachel E. Haurwitz5.00%4.72MApr 22, 2025

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Johnson
Other companies: Vera Therapeutics, Inc. (Chief Operating Officer · Since at least Jul 1, 2024); Exelixis, Inc. (Director · Since at least May 31, 2023); Aura Biosciences, Inc. (Chairman · Since at least Oct 28, 2021); Liquidia Corporation (Board Member · Since at least Apr 13, 2021); Zentalis Pharmaceuticals, Inc. (Director · Since at least Apr 3, 2020); AMAG Pharmaceuticals Inc (Director · Oct 8, 2019 – Nov 16, 2020 · Past); Global Blood Therapeutics Inc (Chief Commercial Officer · Mar 13, 2018 – Oct 5, 2022 · Past); Dynavax Technologies Corporation (Vice President · Feb 5, 2014 – Mar 13, 2020 · Past); Oncotelic Therapeutics Inc (Chief Financial Officer · Apr 2, 2012 – Apr 2, 2012 · Past); Kosan Biosciences Inc (Prin Acct Off & Prin Fin Off · Feb 2, 2006 – Feb 2, 2006 · Past)
Chief Operating Officer · Since at least May 11, 2022
Scott Braunstein
Other companies: AtaiBeckley Inc. (Director · Since at least Jun 4, 2026); RAPT Therapeutics Inc (Director · Since at least Jun 21, 2025); Trevena, Inc. (Operating Partner at Aisling Capital Management LP · Since at least Sep 27, 2018); Protara Therapeutics, Inc. (Director · Jan 9, 2020 – Jun 9, 2020 · Past); Constellation Pharmaceuticals Inc (Director · Feb 19, 2019 – Jul 15, 2021 · Past); Marinus Pharmaceuticals Inc (CHAIRMAN AND CEO, Director · Sep 19, 2018 – Aug 14, 2024 · Past); Alaunos Therapeutics, Inc. (Director · Sep 18, 2018 – Dec 31, 2019 · Past); Pacira BioSciences, Inc. (Chief Operating Officer · Jul 13, 2015 – Jan 3, 2018 · Past); Esperion Therapeutics, Inc. (Director · Jun 15, 2015 – May 29, 2019 · Past)
Operating Partner · Since at least Jul 22, 2021
Andrew Guggenhime
Other companies: Vaxcyte, Inc. (PRESIDENT AND CFO · Since at least Jun 11, 2020); Metacrine Inc (Director · Sep 15, 2020 – May 18, 2022 · Past); Facet Biotech Corp (SVP & CFO · Dec 9, 2008 – Apr 21, 2010 · Past); PDL BioPharma Inc (SVP & Chief Financial Officer · Apr 3, 2006 – Dec 18, 2008 · Past); Neoforma Inc (Chief Financial Officer · Dec 31, 2005 – Dec 31, 2005 · Past)
President and Chief Financial Officer · Since at least Jul 22, 2021
Natalie Sacks
Other companies: Harpoon Therapeutics Inc (Chief Medical Officer · Feb 7, 2019 – Jan 28, 2022 · Past); Zymeworks Inc. (Director · Jan 1, 2019 – Dec 21, 2022 · Past); Aduro Biotech Inc (Chief Medical Officer · Aug 31, 2016 – Sep 12, 2018 · Past)
Partner at Novo Holdings Ventures Investment · Since at least Jul 22, 2021
Jason V. O'Byrne
Other companies: Olema Pharmaceuticals, Inc. (Chief Financial Officer · Since at least Aug 11, 2026); Vir Biotechnology, Inc. (EVP & Chief Financial Officer · Since at least Oct 2, 2024)
Chief Financial Officer · Jul 22, 2021 – Feb 20, 2024 · Past
Rachel Haurwitz
Other companies: Seer, Inc. (Director · Nov 8, 2021 – Jun 12, 2024 · Past); Intellia Therapeutics, Inc. (Director · May 5, 2016 – May 11, 2016 · Past)
President and chief executive officer · Since at least Jul 22, 2021
Sriram Ryali
Other companies: Codexis, Inc. (Chief Financial Officer · Jan 23, 2023 – Jan 1, 2024 · Past); Eiger Biopharmaceuticals Inc (Chief Financial Officer · Dec 17, 2018 – Mar 14, 2022 · Past)
Chief Financial Officer · Since at least Jan 2, 2025
Syed Ali-aamir Rizvi
Other companies: Rocket Pharmaceuticals, Inc. (Chief Medical Officer · Since at least Sep 15, 2025); Poseida Therapeutics Inc (Chief Medical Officer · Apr 1, 2024 – Jan 8, 2025 · Past)
Chief Medical Officer · Jan 18, 2022 – Feb 21, 2023 · Past
Nancy Whiting
Other companies: Boundless Bio, Inc. (Director · Since at least Mar 27, 2024)
President and Chief Executive Officer · Since at least Aug 24, 2021
Timothy P Kelly
Other companies: Q32 Bio Inc. (Chief Operating Officer · Sep 20, 2018 – Feb 24, 2022 · Past)
Chief Technology Officer · Since at least Jan 1, 2024
All 23 people
PersonSeat
Tina M Albertson
Other companies: Lyell Immunopharma, Inc. (Chief Medical Officer · Mar 23, 2022 – Feb 24, 2023 · Past)
Chief Medical Officer · Since at least Aug 12, 2024
Barbara McClungChief Legal Officer and Corporate Secretary · Since at least Jul 22, 2021
Dara Richardson-HeronChief Executive Officer · Since at least Nov 4, 2021
Enrique ZudaireSenior Vice President, Translational Research · Since at least Nov 4, 2026
Jeffrey Stephen Long-McGieDirector · Jul 22, 2021 – Jul 22, 2021 · Past
Justin SkobleSenior Vice President, Technical Operations · Since at least Nov 4, 2026
Ran ZhengChief Executive Officer · Since at least Sep 24, 2021
Reigin ZawadzkiChief People Officer · Since at least Nov 4, 2026
Ruhi Ahmad KhanChief Business Officer · Since at least Nov 8, 2021
Ryan FischesserVP of Finance and Controller · Jul 22, 2021 – Nov 20, 2024 · Past
Sri RyaliChief Financial Officer · Since at least Jan 12, 2025
Steven KannerChief Scientific Officer · Jul 22, 2021 – Feb 20, 2025 · Past
Tina AlbertsonChief Medical Officer · Since at least Mar 31, 2026

Open People

Log in to ask 6ix AI your own questions about Caribou Biosciences, Inc.